Breaking News

Yesterday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Syndicate
Reviva Pharmaceuticals files $150M mixed securities shelf  16:16
01/26/22
01/26
16:16
01/26/22
16:16
RVPH

Reviva Pharmaceuticals

$1.74 /

-0.11 (-5.95%)

 
ShowHide Related Items >><<
RVPH Reviva Pharmaceuticals
$1.74 /

-0.11 (-5.95%)

RVPH Reviva Pharmaceuticals
$1.74 /

-0.11 (-5.95%)

01/24/22 H.C. Wainwright
Reviva Pharmaceuticals initiated with a Buy at H.C. Wainwright
07/26/21 Maxim
Reviva Pharmaceuticals initiated with a Buy at Maxim
07/26/21 Maxim
Reviva Pharmaceuticals initiated with a Buy at Maxim
RVPH Reviva Pharmaceuticals
$1.74 /

-0.11 (-5.95%)

Monday
Initiation
Reviva Pharmaceuticals initiated with a Buy at H.C. Wainwright » 06:07
01/24/22
01/24
06:07
01/24/22
06:07
RVPH

Reviva Pharmaceuticals

$1.74 /

-0.16 (-8.42%)

H.C. Wainwright analyst…

H.C. Wainwright analyst Raghuram Selvaraju initiated coverage of Reviva Pharmaceuticals with a Buy rating and $10 price target. Reviva is an emerging specialty biopharmaceutical company focusing on the development of a next-generation antipsychotic agent, brilaroxazine, Selvaraju tells investors in a research note. The analyst says brilaroxazine "possesses a highly advantageous pharmacological profile."

ShowHide Related Items >><<
RVPH Reviva Pharmaceuticals
$1.74 /

-0.16 (-8.42%)

RVPH Reviva Pharmaceuticals
$1.74 /

-0.16 (-8.42%)

07/26/21 Maxim
Reviva Pharmaceuticals initiated with a Buy at Maxim
07/26/21 Maxim
Reviva Pharmaceuticals initiated with a Buy at Maxim
RVPH Reviva Pharmaceuticals
$1.74 /

-0.16 (-8.42%)

Over a week ago
Hot Stocks
Reviva Pharmaceuticals: FDA clears Phase 3 trial of brilaroxazine » 06:10
01/10/22
01/10
06:10
01/10/22
06:10
RVPH

Reviva Pharmaceuticals

$2.96 /

+0.185 (+6.67%)

Reviva Pharmaceuticals…

Reviva Pharmaceuticals announced the U.S. FDA has notified the company that it may proceed with Phase 3 clinical investigation of its lead candidate, brilaroxazine, a novel serotonin and dopamine receptor modulator for the treatment of schizophrenia. "We believe that FDA clearance to proceed with initiation of a pivotal Phase 3 trial, as well as an additional Phase 3 trial focused on long-term safety, represents a transformative milestone that may support the filing and approval of a new drug application for our lead candidate brilaroxazine in patients with schizophrenia. Both Phase 3 trials will be initiated simultaneously, with the long-term safety study designed to supplement efficacy and safety data from the pivotal trial," said Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva. "Collectively these two trials may provide a robust Phase 3 assessment of brilaroxazine in patients with schizophrenia that we believe will complement our successful Phase 2 study. We remain highly encouraged by the therapeutic potential of brilaroxazine and look forward to initiating both Phase 3 trials by the end of January 2022."

ShowHide Related Items >><<
RVPH Reviva Pharmaceuticals
$2.96 /

+0.185 (+6.67%)

RVPH Reviva Pharmaceuticals
$2.96 /

+0.185 (+6.67%)

07/26/21 Maxim
Reviva Pharmaceuticals initiated with a Buy at Maxim
07/26/21 Maxim
Reviva Pharmaceuticals initiated with a Buy at Maxim
RVPH Reviva Pharmaceuticals
$2.96 /

+0.185 (+6.67%)

Over a month ago
Earnings
Reviva Pharmaceuticals reports Q3 EPS (12c), consensus (23c) » 08:20
11/15/21
11/15
08:20
11/15/21
08:20
RVPH

Reviva Pharmaceuticals

$3.69 /

+0.03 (+0.82%)

As of September 30, the…

As of September 30, the company's cash totaled approximately $33.5M compared to approximately $0.35M a year ago."We look forward to initiating two Phase 3 trials evaluating both the efficacy and safety, as well as long-term safety of brilaroxazine in adults with schizophrenia by year-end," said CEO of Reviva. "We are highly encouraged by the therapeutic potential brilaroxazine demonstrated in our successful Phase 2 trial for the treatment of schizophrenia and expect to begin regulatory submissions to the FDA for pulmonary indications including IPF and PAH by the end of 3Q22."

ShowHide Related Items >><<
RVPH Reviva Pharmaceuticals
$3.69 /

+0.03 (+0.82%)

RVPH Reviva Pharmaceuticals
$3.69 /

+0.03 (+0.82%)

07/26/21 Maxim
Reviva Pharmaceuticals initiated with a Buy at Maxim
07/26/21 Maxim
Reviva Pharmaceuticals initiated with a Buy at Maxim
RVPH Reviva Pharmaceuticals
$3.69 /

+0.03 (+0.82%)

RVPH Reviva Pharmaceuticals
$3.69 /

+0.03 (+0.82%)

Over a quarter ago
Hot Stocks
Reviva Pharmaceuticals announces 2021 anticipated events, targeted milestones » 08:52
08/16/21
08/16
08:52
08/16/21
08:52
RVPH

Reviva Pharmaceuticals

$3.48 /

+0.03 (+0.87%)

Anticipated Events and…

Anticipated Events and Targeted Milestones for 2021: Initiate a pivotal, double-blind Phase 3 study in acute schizophrenia; Regulatory submissions to the U.S. Food and Drug Administration for initiating Phase 2 studies in pulmonary arterial hypertension and idiopathic pulmonary fibrosis; Pursue partnership opportunities for the development of our pipeline; Evaluate grant and other non-dilutive financing opportunities for our product candidates from relevant Federal and State Agencies and Foundations

ShowHide Related Items >><<
RVPH Reviva Pharmaceuticals
$3.48 /

+0.03 (+0.87%)

RVPH Reviva Pharmaceuticals
$3.48 /

+0.03 (+0.87%)

07/26/21 Maxim
Reviva Pharmaceuticals initiated with a Buy at Maxim
07/26/21 Maxim
Reviva Pharmaceuticals initiated with a Buy at Maxim
RVPH Reviva Pharmaceuticals
$3.48 /

+0.03 (+0.87%)

RVPH Reviva Pharmaceuticals
$3.48 /

+0.03 (+0.87%)

Hot Stocks
Reviva Pharmaceuticals expects cash to cover expenses into 2H22 » 08:52
08/16/21
08/16
08:52
08/16/21
08:52
RVPH

Reviva Pharmaceuticals

$3.48 /

+0.03 (+0.87%)

As of June 30, 2021, the…

As of June 30, 2021, the Company's cash and cash equivalents totaled approximately $35.8 million compared to approximately $0.2 million for the same period in 2020. Reviva believes that based on the current operating plan and financial resources, the Company's cash and cash equivalents at the quarter end June 30, 2021 will be sufficient to cover general operating expenses into the second half of 2022.

ShowHide Related Items >><<
RVPH Reviva Pharmaceuticals
$3.48 /

+0.03 (+0.87%)

RVPH Reviva Pharmaceuticals
$3.48 /

+0.03 (+0.87%)

07/26/21 Maxim
Reviva Pharmaceuticals initiated with a Buy at Maxim
07/26/21 Maxim
Reviva Pharmaceuticals initiated with a Buy at Maxim
RVPH Reviva Pharmaceuticals
$3.48 /

+0.03 (+0.87%)

RVPH Reviva Pharmaceuticals
$3.48 /

+0.03 (+0.87%)

Earnings
Reviva Pharmaceuticals reports Q2 EPS (23c) vs. (58c) last year » 08:51
08/16/21
08/16
08:51
08/16/21
08:51
RVPH

Reviva Pharmaceuticals

$3.48 /

+0.03 (+0.87%)

"We believe the…

"We believe the recent closing of our successful public offering, resulting in gross proceeds of $34.5 million, supported by institutional investors, provides the capital resources to proceed with a pivotal Phase 3 trial of brilaroxazine in patients with schizophrenia," said Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva. "Brilaroxazine demonstrated clinical benefit across the hallmark symptoms of schizophrenia and we expect to initiate our upcoming Phase 3 trial in Q4-2021."

ShowHide Related Items >><<
RVPH Reviva Pharmaceuticals
$3.48 /

+0.03 (+0.87%)

RVPH Reviva Pharmaceuticals
$3.48 /

+0.03 (+0.87%)

07/26/21 Maxim
Reviva Pharmaceuticals initiated with a Buy at Maxim
07/26/21 Maxim
Reviva Pharmaceuticals initiated with a Buy at Maxim
RVPH Reviva Pharmaceuticals
$3.48 /

+0.03 (+0.87%)

RVPH Reviva Pharmaceuticals
$3.48 /

+0.03 (+0.87%)

Initiation
Reviva Pharmaceuticals initiated with a Buy at Maxim » 08:03
07/26/21
07/26
08:03
07/26/21
08:03
RVPH

Reviva Pharmaceuticals

$3.81 /

-0.205 (-5.11%)

Maxim analyst Jason…

Maxim analyst Jason McCarthy initiated coverage of Reviva Pharmaceuticals with a Buy rating and $10 price target. The company is developing its lead asset, RP5063, for the treatment of schizophrenia and respiratory indications including idiopathic pulmonary fibrosis and pulmonary arterial hypertension, the analyst tells investors in a research note. Reviva's RP5063 features a multimodal mechanism of action, which is "more completely" addressing the mix of positive, negative, and cognitive symptoms associated with schizophrenia, McCarthy adds.

ShowHide Related Items >><<
RVPH Reviva Pharmaceuticals
$3.81 /

-0.205 (-5.11%)

RVPH Reviva Pharmaceuticals
$3.81 /

-0.205 (-5.11%)

07/26/21 Maxim
Reviva Pharmaceuticals initiated with a Buy at Maxim
RVPH Reviva Pharmaceuticals
$3.81 /

-0.205 (-5.11%)

RVPH Reviva Pharmaceuticals
$3.81 /

-0.205 (-5.11%)

Initiation
Reviva Pharmaceuticals initiated with a Buy at Maxim » 07:47
07/26/21
07/26
07:47
07/26/21
07:47
RVPH

Reviva Pharmaceuticals

$3.81 /

-0.205 (-5.11%)

Maxim analyst Jason…

Maxim analyst Jason McCarthy initiated coverage of Reviva Pharmaceuticals with a Buy rating and $10 price target.

ShowHide Related Items >><<
RVPH Reviva Pharmaceuticals
$3.81 /

-0.205 (-5.11%)

RVPH Reviva Pharmaceuticals
$3.81 /

-0.205 (-5.11%)

RVPH Reviva Pharmaceuticals
$3.81 /

-0.205 (-5.11%)

Hot Stocks
Reviva Pharmaceuticals added to Russell Microcap Index » 07:14
06/28/21
06/28
07:14
06/28/21
07:14
RVPH

Reviva Pharmaceuticals

$4.99 /

+0.01 (+0.20%)

Reviva Pharmaceuticals…

Reviva Pharmaceuticals Holdings announced it has joined the broad-market Russell Microcap Index at the conclusion of the Russell U.S. Indexes annual reconstitution. The updated Index will become effective after the U.S. equity market opens today, Monday June 28, 2021.

ShowHide Related Items >><<
RVPH Reviva Pharmaceuticals
$4.99 /

+0.01 (+0.20%)

RVPH Reviva Pharmaceuticals
$4.99 /

+0.01 (+0.20%)

RVPH Reviva Pharmaceuticals
$4.99 /

+0.01 (+0.20%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.